Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes (EVIDENCE)

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: liraglutide

Study type: Observational

Funder types: Industry

Identifiers

NCT01226966

U1111-1116-2722 (Other Identifier)

NN2211-3815

Details and patient eligibility

About

This observational study is conducted in Europe. The aim of this non-interventional (observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the conditions of use of Victoza® in daily medical practice in France.

Enrollment: 3,152 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with type 2 diabetes
• Patients having recently started (for less than one week) or starting liraglutide (Victoza®) treatment

Exclusion criteria

• Hypersensitivity (allergy) to liraglutide or to any of the excipients
• Patient is participating in a clinical trial at the inclusion
• Type 1 diabetes

Trial design

3,152 participants in 1 patient group

A

Treatment:

Drug: liraglutide